Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Cell & Gene Therapy Asia 2019

Keiya Ozawa's Biography



Keiya Ozawa, Professor Emeritus and Visiting Professor of the Division of Immuno-Gene & Cell Therapy, Jichi Medical University

Keiya Ozawa received his M.D. from University of Tokyo in 1977 and his Ph.D. from University of Tokyo in 1984. After the residency in Internal Medicine at Tokyo University Hospital (1977-79), he became Research Associate of Jichi Medical School (1980-82) and University of Tokyo (1984-87). He studied at the Clinical Hematology Branch, NHLBI, NIH, USA as a Fogarty Fellow (1985-87). He became Assistant Professor in 1987 and then Associate Professor in 1990 of The Institute of Medical Science, The University of Tokyo (IMSUT). In 1994 he became Professor of the Institute of Hematology, Jichi Medical School. He was Professor and Chairman of the Division of Hematology, Department of Medicine (1998-2014) and Professor of the Division of Genetic Therapeutics, Center for Molecular Medicine (1998-2014). He was Director of Center for Molecular Medicine, Jichi Medical University (2008-14). He was also Professor of the Division of Immuno-Gene & Cell Therapy (Takara Bio), Jichi Medical University (2011-14). He was Director of IMSUT Hospital and Professor of the Division of Genetic Therapeutics, The Advanced Clinical Research Center, IMSUT (2014-18). He was also Director of Center for Gene & Cell Therapy (CGCT) of IMSUT (2014-18). In 2018, he became Professor Emeritus and Visiting Professor of the Division of Immuno-Gene & Cell Therapy (Takara Bio), Jichi Medical University. He is also Senior Adviser of the Center for Gene Therapy Research (CGTR), Jichi Medical University (2018- ). Dr. Ozawa has authored 470 original scientific and medical articles and 59 reviews and book chapters. Dr. Ozawa is a member of American Society of Hematology, American Society of Gene & Cell Therapy, European Hematology Association, European Society of Gene & Cell Therapy, The New York Academy of Sciences and so on.

Keiya Ozawa Image

Current Status and Future Directions of CAR-T Cell Therapy

Monday, 11 November 2019 at 09:00

Add to Calendar ▼2019-11-11 09:00:002019-11-11 10:00:00Europe/LondonCurrent Status and Future Directions of CAR-T Cell TherapyCell and Gene Therapy Asia 2019 in Kobe, JapanKobe, JapanSELECTBIOenquiries@selectbiosciences.com

Adoptive immunotherapy with CAR (chimeric antigen receptor)-T cells is a promising cell-based anticancer therapy for hematological malignancies. CARs are hybrid proteins consisting of an extracellular single chain fragment of variable region (scFv) fused to intracellular lymphocyte signaling domains CD28 or 4-1BB, coupled with CD3 to mediate T cell activation. CD19-targeted CAR-T cell therapy showed surprising clinical efficacy against relapsed/refractory acute lymphoblastic leukemia and malignant lymphoma. In 2017, this novel treatment was approved by FDA in USA. Cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and tumor lysis syndrome (TLS) are adverse effects that appear at an early stage following the infusion of CAR-T cells. Delayed onset toxicity of CD19-CAR-T cell therapy is the serum immunoglobulin deficiency due to destruction of normal B cells (on-target, off-tumor reaction). A next promising target antigen is considered to be BCMA (B cell maturation antigen), and BCMA-CAR-T cell therapy has been shown to be effective against multiple myeloma. On the other hand, the efficacy of CAR-T cell therapy for solid tumors has been unclear. There are several issues to be solved, and CAR-T for solid tumors should be combined with other therapeutic technologies. Currently, genome editing technology is rapidly progressing, and its application to gene-modified T cell therapy is being conducted; e.g. 1) TCR gene knockout for allogeneic (universal) CAR-T cell therapy and 2) PD-1 gene knockout of CAR-T cells (immune checkpoint blockade) to increase its cytotoxic activity. Another major issue is that gene therapies recently approved in Europe and the U.S. are extremely expensive.


Add to Calendar ▼2019-11-11 00:00:002019-11-12 00:00:00Europe/LondonCell and Gene Therapy Asia 2019Cell and Gene Therapy Asia 2019 in Kobe, JapanKobe, JapanSELECTBIOenquiries@selectbiosciences.com